ロード中...
Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial
BACKGROUND: Although platinum-based chemotherapy is accepted as adjuvant chemotherapy for resectable advanced non-small cell lung cancer (NSCLC), its completion rate is low due to severe adverse events. S-1 plus cisplatin is associated with relatively low toxicity and an unimpaired quality of life,...
保存先:
| 出版年: | J Thorac Dis |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8107543/ https://ncbi.nlm.nih.gov/pubmed/34012573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd-20-3293 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|